3rd World-China Biosimilars & Novel Vaccines Forum 2016
Vice-chair of the Commission for Human Medicines (CHM)
After qualifying in Medicine from the University of London in 1980, I trained in general medicine and then adult haematology, subsequently developing a special interest in paediatrics. I was a fellow in molecular biology at University College London and was awarded a PhD on Genetic Variation of the Fibrinogen Gene.
I was appointed in 1992 as a consultant paediatric haematologist at the Royal Hospital for Sick Children in Edinburgh and am director of the Haemophilia Centre at the Edinburgh Royal Infirmary. I care for children with a wide range of haematological disorders, including those with leukaemia, immune deficiency, haemolytic anaemias and bleeding disorders. I was president of the British Society for Haematology in 2012-2013.
In addition to my clinical post, I am vice-chair of the Commission for Human Medicines (CHM) and chair its Clinical Trials, Biologicals and Vaccines Expert Advisory Group. The CHM advises on the quality, safety and efficacy of human medicinal products and advises the Licensing Authority on the granting of a licence for such products.
Donald W. Wyatt
Vice-President of Business Development and Alliance Management
Liaoning Sansei Pharmaceutcal Co., Ltd.(3SBIO.Inc.)
Donald Wyatt has over twenty years experience in technology companies. He has worked in research, legal affairs and management with experience in North America, Europe and Asia, and especially China. He has served in both senior management and board of director positions for technology development and commercial companies. Mr. Wyatt started his career with a bachelor's degree in biochemistry and since then has earned a master's degree in intellectual property, doctorate of laws and an MBA. This diverse background has led Mr. Wyatt to be particularly interested in the management of intellectual property at a strategic level. He specializes in systems and processes for streamlining intellectual property processes to align them with corporate strategy.
Application Marketing manager
Deng received his doctor degree in 2005 at Department of Immunology, School of Medicine, Fudan University (a key laboratory in Molecular Medicine Ministry of Education). Afterwards he worked as R&D manager in several companies such as Roche and Alere. In 2014, he joined Proteinsimple China and now he acts as application marketing manager in China region and is responsible for the market promotion of proteinsimple products in China.
Medical Development Director
Dr. Jacqueline Huang currently serves as Medical Development Director in Amgen, overseeing medical development function in Amgen China.
Dr. Huang is a physician by training with clinical practice in internal medicine, hematology and oncology, as well as a research fellowship in molecular biology. Prior to Amgen, Dr. Huang worked with Aventis and Novartis, held evolving roles through different organization areas including the country organization, Asia-Pacific region and global organization, leading global development programs, regional and local medical activities.
Dr. Huang received her MD from Shanghai Medical University with further training in its Graduated School, gained research experience in Shang Institute of Hematology / Ruijing Hospital, and spent years of clinical practice in Shanghai ZhongShan Hospital and Shanghai Cancer Hospital.
CPGJ Research Institute, Shanghai CP Guojian Pharmaceutical Co., Ltd.
Hui has 15 years’ experience in biologics R&D, cGMP quality operations, and Bioengineering design. After graduated from ECUST, Hui joined Shanghai CP Guojian Pharmaceutical Co., Ltd. as a R&D researcher. He focused on developing the process of cell culture and engineering design. In particular, he has extensive experience in genetically engineered E. coli and CHO high density and large-scale cultivation. There are two antibody drugs that CP Guojian developed on the market. He was responsible for USP development. He led to design the first 2*3000L scale and the first 6*5000L scale GMP facility for antibody in China.
Regional Director APAC
Komtur Pharmaceuticals Group
Jan Oesterreich has been living and working in China and Asia since more than 17 years. After graduating as Master of Sinological Business Studies in Germany with study terms at Tongji University, research internships in Beijing and two years of medical studies prior to this, he joined Komtur Pharmaceuticals in 2002. Within the group which is one of the leading independent global sourcing specialists for clinical trial comparator drugs Jan has served in different management positions and is leading the regional office for Asia-Pacific in Shanghai since 2008.
tenured Associate Professor
Thayer School of Engineering at Dartmouth
Dr. Karl Griswold’s work in the field of protein engineering has resulted in the development of new tools for protein deimmunization, enhanced microbial production systems, novel strategies for gene library construction, and new approaches to high throughput screening of recombinant protein libraries. He studied as a DOW Foundation Scholar at Texas State University, graduating summa cum laude in 1995. He received his Ph.D. from the University of Texas at Austin in 2005, and completed a postdoctoral fellowship under Professor George Georgiou at the University of Texas. Dr. Griswold’s recent honors include a “Teacher of the Year” award from the Thayer School of Engineering and a “Young Investigator Award in Translational Biomedical Engineering” from the Coulter Foundation. He has coauthored more than 40 peer-reviewed articles, has patented numerous inventions relating to both synthetic chemistry and biotechnology, and has secured more than $10M in grants to support his research.He co-founded and serves as the CEO of the biotechnology startup Stealth Biologics LLC, which has developed proprietary biotherapeutic design and deimmunization platforms that are advancing programs with numerous biopharma partners.
VP, Process Sciences,
– Ph.D. University of Washington, Seattle
– 20+ years experience in cell line development and biologics research in US China and Taiwan
– Developed production cell lines to support several BLA and IND filings including those for Remicade, Simponi and Stelara
– Johnson and Johnson Philip B. Hoffmann Award winner (2003）
– Prestigious Scholar Award from Jiangsu province and Zhejiang province, China
– VP, Biologics Research, PharmaEssentia
– VP, Preclinical Study and Cell Line Development, Zhejiang Teruisi Pharmaceutical Inc.
– Executive Director, Biologics Research, Simcere Pharmaceutical R&D Inc.
– Senior Director , Biologics and Reagent Generation, Wuxi AppTec (China)
– Research Fellow (Associate Director equivalent), Pharmaceutical Development, Centocor, JNJ; Medimmune, AZ
– Staff Scientist, Mammalian Expression, Regeneron
– Senior Research Associate, Immunex/Amgen
Simcere Pharmaceutical Group
Dr. Jingrong Li has studied and worked abroad for 19 years and has worked in large international enterprises for 12 years. He has in-depth knowledge about GMP policies from FDA, EU, WHO, ISO and countries like Canada and Japan and has accumulated rich experience in dealing with various kinds of inspection. During his 8 year in Roche, he has experienced hundreds of high standard inspections from FDA, ISO, EU and WHO and has successfully passed all the inspections with high efficiency. During his work time in US pharmaceutical enterprises, he has taken lead eight research projects and six of them have already launched products. Each product’ revenue has reached over 100mln US dollars. Dr. Li is also responsible for writing, checking and authorizing relevant production documents. He has successfully coordinated with FDA assessors and won reputation for the company.
As a Vice President at Innovent Biologics, I am responsible for all aspects of the GMP compliance and Quality management responsibilities that support the biologics development pipeline at Innovent. I am also overall responsible for the commercialization efforts at Innovent.
I was born and raised in Shanghai and went to Fudan University. In 1987, I went to the US and obtained my Ph.D degree in Cell and Molecular Biology from University of California at Berkeley, and conducted breast cancer research during post-doctoral training before working in the pharmaceutical industry for nearly 20 years. The earlier part of my career was focused on R&D and IND-enabling research. For the past 12 years, my career was focused on analytical methods, manufacturing and Quality. I am an experienced and recognized Quality leader in the biotechnology industry in the US, prior to coming back to China in April 2015. I was head of Quality for Bayer Healthcare Biotech division responsible for all biotech products in clinical development. Prior to Bayer, I held various Quality leadership positions Genentech/ROCHE including managing QA and QC functions for clinical development, as well as commercial products. My Quality leadership expertise reflects the current global regulatory environment using science and risk based approach, coupled with an integrated Quality system as the basis for effective Quality management. I have personally involved in the global product quality management of nearly all Genentech biologics such as Avastin, Herception and Perjeta, and tech transfers post ROCHE-Genentech merger. I have also overseen >10 products during clinical development including MPDL.
My business leadership experience include fast growing small companies to multinational global pharmaceuticals and have a proven track record of successful leadership and people management. I have been a regular conference speaker in the US on Quality systems and Biotech Quality management.
President & CEO
Shanghai Henlius Biotech Co., Ltd.
Dr. Scott Liu, graduated from Purdue University, Department of Biology, was a postdoctoral fellow at Stanford University, and later pursued iMBA courses at Syracuse University. As the Founder, President and CEO of Henlius Biopharmaceuticals, Inc. and Shanghai Henlius Biotech Co., Ltd., he takes overall responsibility for strategic planning and implementation, as well as operation management. Benefiting from Scott’s vision in achieving quality at reasonable cost, Shanghai Henlius Biotech Co., Ltd. has adopted advanced technologies in mAb development and manufacturing, and, in doing so, significantly reduced the manufacturing costs while maintaining the quality of the products.
Before founding his own companies, Scott held key technical and/or leadership positions in several leading biopharmaceutical companies, including Amgen, Bristol-Myers Squibb, United Biomedicals (UBI), Tanox and Maxygen.
He was the Director of Quality Analytical Labs of Amgen-Fremont, and took responsibility for quality control operations for late-phase development and cGMPcommercial manufacturing of Vectibix. Prior to Amgen, Scott held the post of Associate Director of Biologics QC in BMS-Syracuse, he was in charge of QC operations for late phase development and commercial manufacturing of Orencia.
Dr. Liu has 20 years’ experience of biopharmaceutical development, manufacturing, drug administration and quality management , and he won the title of " 1000 Planning Expert of Shanghai " in 2013.
Jianshun Biosciences Co., Ltd.
Before he founded Jianshun Biosciences Co., Ltd. Dr. Shun Luo was the director of Research and Development at JRH Biosciences, Inc. and Dr. Luo was also the director of free serum cell culture and Research Department at Genentech. In addition, Dr. Shun Luo was the director of Cell Science & Technology at Amgen, which is the biggest biotech company in the world. Dr. Luo made great achievements when he was the director of Research and Development at Sigma SAFC Company. Dr. Luo made a name for himself in the world for getting the top protein production when he lead the CHO cell culture group in Genentech, GeneXP Biosciences, and also Amgen.
Dr. Shun Luo completed his Ph.D. degree at Virginia Polytechnic Institute & State University in 1992. He received his post doctorate in the Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, at Harvard Medical School in 1993.
Dr. Shun Luo is an inventor of 7 U.S. patents. Dr. Luo is also the inventor of gene of FcgRIII polymorphic isoforms (2 US Patents, 9 Pending Patents). In 2010, The Grand Prize of Scientific and Technological Innovation of Amgen was awarded to Dr. Shun Luo for his great achievement in cell culture and the protein production achieved of 11g/L which is the highest production in the world. Dr. Luo is often invited to participate in the cell culture technological science international conference as the main speaker. Dr. Shun Luo is well respected and holds a high academic position in this field.
R&D Director of Antibody
He is responsible for the research and development of antibody drugs in Hisun Pharmaceutical. Through eight years of efforts, one of the mAb projects have entered clinical trials, two other projects have received clinical approval.
Senior VP R&D
Livzon MabPharm Inc
Dr. Peng received his Ph.D. from McGill University and has studied and worked respectively in Wuhan University, Peking University, New York Medical College, McGill University and New England Medical Center. He has more than 15 year working experience in both US and China biopharmaceutical enterprises and worked previously as a senior scientist and group leader at Biogen Idec. His technical expertise cover process development, analytical development, quality control, regulatory affairs, and preclinical/clinical development.
Senior Scientist and Clinical Assessor
Norwegian Medicines Agency
PhD 1996 in Molecular Biology
1996-2003: Post doc and project leader on the development methods to detect abuse of epoetins among athletes in sports, at the Section for Doping analyses, Hormone Laboratory, Oslo University Hospital, Norway.
Skibeli V., Nissen-Lie G., Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood, 98
2003-2006: Senior Scientist and Project leader in glycobiology at the Department of Molecular Biological Sciences, University of Oslo, Norway.
Tveit H., Dick G., Skibeli V. and Prydz K.. A proteoglycan undergoes different modifications en route to the apical and basolateral surfaces of Madin-Darby Canine Kidney cells., Journal of Biological Chemistry, 280, p.29569, 2005.
2006- today: Senior Scientist and Clinical Assessor at the Norwegian Medicines Agency mainly in oncology, advanced therapies and biosimilars.
VP of Technical Operation and Process Development
MabSpace Biosciences Co., Ltd
Dr. Wu has more than 15 years of US biotech industry experience in CMC development of monoclonal antibody and recombinant protein therapeutics. In the past few years, his work focused on building the CHO-based monoclonal antibody technology platforms for biosimilar and biobetter in China. Dr. Wu has a Ph.D. in Biochemistry from Simon Fraser University, Canada and completed his postdoctoral fellowship at Stanford University Medical School, USA. He currently severs as VP of Technical Operation and Process Development at MabSpace Biosciences (Suzhou) Co. Ltd.; Prior to this position, he was the VP of R&D and Head of Biologics at Fujian Haixi Pharmaceutical Inc.
Dr. Zheru Zhang has over 20 years of biopharmaceutical research and development experiences in multiple therapeutic areas. Dr. Zhang’s experiences include monoclonal antibody development from early development to BLA filing, especially in the areas of analytical development, CMC strategy and cGMP compliance, as well as on comparability study and mAb biosimilar development. He worked for Bristol Myers Squibb in NJ, Johnson & Johnson Centocor in PA, and Celltrion in Incheon, Korea and contributed to over 15 IND and BLA filings. Prior to current job, he was CEO at Shanghai JMT-Bio Inc.
Dr. Zhu is an expert in antibody drug discovery and process development with more than 15 years of industrial experience. He has extensive experience in antibody drug discovery, cell line and process development, and manufacture facility construction. In March 2014, Dr. Zhu joined Huahai Pharm and led its global biological research as CEOs for Huaota Biopharmaceuticals and Huabo Pharmaceuticals. Prior to joining Huahai, he worked with Boehringer Ingelheim for more than 8 years in different function areas at multiple locations: ( Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led and engaged a number of biological research projects including current clinic study projects, and market products. Dr. Zhu is a receiver of the “National Thousand Talent” and has also received awards from Zhejiang province as the leader of an innovative biotherapeutical discovery team in 2014.
Beijing Combio Pharma. Inc.
Dr. Zhu Xiaodong is currently the CEO of Beijing Combio Pharma. In January 2014, he co-founded Beijing Combio Pharma in China.Dr. Zhu obtained Ph.D degree majored in Molecular Virology from Institute of Microbiology, Chinese Academy of Sciences and pursued his postdoctoral training at University of California at San Francisco (UCSF) in 2004. He was appointed as Research Specialist in the Department of Anesthesia at UCSF in 2008.In the well-known domestic and foreign magazine he has published more than 20 papers, applications and granted four US patents and china patents. He was elected to the American Gastroenterological Association (AGA) member, former Chairman of the Chinese Medical Association of North America (CABS) branch committee. He was involved in the development of innovative antibody drugs and biosimilar drugs, preclinical declaration at projects of National Key New Drug Creation .
Novel Vaccines Forum
Distinguished Research Fellow & Professor
Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
Dr. Chen was the founding Director General (2004-2008) of the Guangzhou Institute of Biomedicine and Health, a newly established institute in the Chinese Academy of Sciences. From 2009-2012, Dr. Chen served as Vice Presidents of R&D for GlaxoSmithKline and as Vice President, Head of China Vaccine R&D at Sanofi Pasteur respectively. Dr. Chen received medical degree from Shanghai Medical College (Fudan University) in 1984. He was selected as a CUSBEA Fellow in 1984 to pursue a Ph.D. in Indiana University School of Medicine, USA. From 1992-1996, Dr. Chen was a postdoctoral fellow and then became an Instructor at the Dana-Farber Cancer Institute, Harvard Medical School. From 1997-2001, Dr. Chen served a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor on Merck’s MRK Ad5 based AIDS vaccine (US6787351) that entered phase IIb clinical trial worldwide. Dr. Chen is currently working on developing novel vaccines for infectious diseases.
Director of Research Center
Ki-Hwan Kim Ph.D. is the director of research center of JW Creagene in Korea. She was admitted to the College of Pharmacy of Ewha Womans University in 1993, and obtained Ph.D. in 1999. During this period, she was a research assistant of Lab of Immunology of Korea Cancer Center Hospital, which is affiliated with Korea Institute of Radiological & Medical Sciences (KIRAMS). Since then, she has been working on immunology research. In 2000-2006, she completed her postdoc training in molecular life science and technology (MLST) at the Ewha Womans University and engaged in research in Lab of Cancer Biology of Hormel Institute at University of Minnesota in USA and in Lab of Genetics of the center of cancer research at States national institutes of health in USA. Subsequently, she served as chief researcher of JW Pharmaceuticals & Chugai and Roche Group. In 2011, she joined JW Creagene. She took part in and led many research projects such as Development of anti-inflammatory medicine and Investigational clinical study against hepatocellular carcinoma , rheumatoid arthritis and glioblastoma multiform.
Institute of Medical Biology Chinese Academy of Medical Sciences
Dr. Li graduated from Peking Union Medical College and acquired biology postdoctoral at the Massachusetts Institute of Technology in 1992-1995. Dr. Li entered the “National Talents Project” in 1998 and achieved 2009-2010 “Outstanding Mid-Aged Expert of the Ministry of Public Health”. Dr. Li presided over more than 20 major projects, such as the national "863" plan project, China and the United States CIPRA project sub topics. Dr. Li mainly engages in the virus combined with receptor cells induced early gene research, structural dynamics and recombinant virus research and viral vaccine development research. And his research direction is virus immunology, the development and quality control of molecular biology of the virus vaccine.
Margaret A. Liu
Professor, President of the International Society for Vaccines
Margaret A. Liu, obtained an M.D. from Harvard Medical School, a B.A. in Chemistry, summa cum laude, from Colorado College, passed the Epreuve pour le Diplômed’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the EcoleNormale de Musique de Paris, and is the recipient of an honorary Doctorate of Science. She completed Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School. She received Board Certification in Internal Medicine and in Endocrinology and Metabolism. Dr. Liu was a Visiting Scientist at the Massachusetts Institute of Technology, Instructor at Harvard Medical School, Adjunct Assistant Professor of Medicine at the University of Pennsylvania, a Visiting Professor at the Karolinska Institutet in Stockholm, and the recipient of an NIH Physician Scientist Award. She served as Senior Director at Merck Research Laboratories, Vice President of Vaccines Research and Gene Therapy at Chiron Corporation, Vice-Chairman of Transgène, Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, Executive Vice-Chair of the International Vaccine Institute, and was on the NIH NIAID Council.
Her research has focused on novel technologies for vaccines and immune treatments for cancer. She pioneered the development of DNA vaccines, which are now in clinical trials for many human diseases and are licensed for several veterinary applications. She also was an innovator in the field of bispecific antibodies to activate T cells for tumor cell killing. The Nobel Committee invited her to lecture in the Karolinska Research Lecture series, and she was named by Discover magazine as one of the 50 most important female scientists.
Dr. Liu is the President of the International Society for Vaccines. She consults world-wide for companies, investment firms, non-governmental organizations, and governmental scientific advisory bodies, is an Adjunct Full Professor at UCSF, and is a Foreign Adjunct Professor at the Karolinska Institutet in Stockholm where her work has focused upon HIV vaccines and cancer immunotherapy.
Hualan Biological Bacterin Co., Ltd.,
Ruowen Pan received her bachelor's degree in biochemistry at East China University of Science & Technology and afterwards worked for Xinxiang Medical College as a teacher. From 1993 to 2000, she worked for Hualan Biological Engineering Co., Ltd. as manager of QA department. From 2000 to 2002, Pan continued to study at Henan Normal University in zoology and received master’s degree. From 2000 to now, Pan worked for Hualan as vice general manager and from 2013 to now, as general manager of Hualan Biological Bacterin Co., Ltd. Her main awards include “Second Prize of Henan Scientific and Technological Progress” for ”Human Immunoglobulin for Intravenous Injection”, “Second Prize of Torch Program” for “Human Albumin” and “econd prize for medical science and technology progress in Henan” for “HIN1 Influenza Vaccine (split virion)”. In addition, she has published several papers in vaccine area.
Shanghai Zerun Biotechnology Co., Ltd.
Dr. Li Shi is currently leading Zerun Bio focusing on human vaccine development and commercialization. Zerun Bio is recognized by national governement as a high-tech enterpreure and achieved success M&A with Walvax in 2013. Prior to joining Zerun Bio in early 2011, Dr. Shi had 25 years of experience in USA for vaccine, protein and gene therapgy product development as well as bioprocess and manufacturing support during his tenure in Merck and Genzyme. He made multiple key contributions to Merck’s Gardasil® vaccine development and involved from research stage to clinical developments and commercial manufacturing validation. The success of Gardasil® vaccine, allowed Merck team received 2006 ACS Best Bioprocess Award, and 2007 World Pre-Galen Award, called world pharmaceutical industrial Nobel Prize. The product achieved annual sell of over $2 billion.Dr. Shi received BS/MS from Peking University, Ph.D. from University of California, and postdoctoral and MBA trainings from Scripps and Lehigh University, respectively. He has over 140 paper, patent, and presentation publications. He is a winner of W. H. Person’s Award of American Chemical Society, a former president and co-founder of SAPA-GP. He serves as a reviewer/editor for 12 international journals and NIH fund in the field and as council members in DIA-China advisory committee, USP global biologics expert committee, and Shanghai Biopharma Industrial Association.
Research Associate, Unit of Anti-infection immunity and vaccine research
Institut Pasteur of Shanghai, CAS
Dr. Song received his bachelor degree in Biological Sciences from Zhejiang University in 2006. From 2006 to 2012, he studied at Institut Pasteur of Shanghai, CAS, Unit of Anti-infection immunity and vaccine research and received his doctor degree. In Ph.D. study, we developed a new HIV-1 virus-like particle (VLP) large scale producing system based on stable transfected drosophila S2 cells. The protein process, glycosylation pattern and morphology of HIV-1 VLPs produced by the system were similar to the wild type viruses. More over, the HIV-1 VLPs had good immunogenicity in mouse model. Now, we still focus on new VLP (Rabies VLP) expressing, identification as well as immunogenicity study. We also developed novel chimpanzee adenovirus vectors expressing artificial miRNA to against influenza virus infection. We developed various recombinant chimpanzee adenovirus vectors against virus (influenza, EV71 and so on) as well as tumors and investigate the mechanisms of the immune protection to provide new strategies for disease prevention and control. Mean while, we developed novel influenza virus infection mouse model and investigated the mechanisms of pathogenesis of the model, which would provide more suitable platform for anti-influenza vaccine or drug efficiency evaluation.
Sr. Marketing Manager
BD Medical-Pharmaceutical Systems
Graduated from Shandong University with Master Degree of Medicine. 9 years working experience with prefillable drug delivery systems, familiar with their clinical applications and trends for both international and domestic pharmaceutical market. Used to work as National Manager of Customer Quality Assurance and Technical Service, full knowledge about the cutting-edge technology of manufacturing process and quality systems for prefillable syringes, as well as the applications on various drugs.
Fudan University Shanghai Medical College
Dr. Bin Wang is a professor at Fudan University Shanghai Medical College. His research area is to focus on the effects of DNA vaccine on T cell activations and mechanism of T regulatory cell induced by co-immunization of DNA and protein vaccines. By using this technology, he developed a novel therapeutic vaccination against autoimmune diseases, including type 1 diabetes, asthma and allergy. His other research interest is in the development of novel adjuvants to enhance immune efficacy for current vaccines.
He received his B.A. in biology from Shandong University in 1982 and his Ph.D. from the University Of Cincinnati School Of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute 1992 when he first demonstrated DNA vaccination against HIV-1 in clinical trials. He became an instructor and then assistant professor at University of Pennsylvania Medical School in the period of 1993 to 1998. He was a professor and served as the Chairman at Department of Microbiology and Immunology for 6 years at College of Biological Sciences, China Agricultural University before he joined to Fudan University. He has published over 130 peer-review articles and awarded 10 US and12 Chinese patents. He serves as editorial board members for several international journals and executive membersin number of scientific societies.
Chief Scientist for Epidemiology
Chinese Center for Disease Control and Prevention
Chief Epidemiologist in Chinese Center for Disease Control and Prevention
Member of Health Emergency Advisory Committee, NHFPC
Advisory Expert of the National Basic Research Program ofChina(973 Program)
Founder and Honorary Advisor of Chinese Field Epidemiology Training Program (CFETP)
Expert Consultative Committee Member ofBeijingMunicipal People's Government
Counsellor of Beijing Municipal People's Government
Beijing Zheife Lvzhu Biopharmaceutical Co.,Ltd
Trained in biotechnology engineering, Dr. Zhang graduated from Northwestern Agriculture University in China and has over ten years of experience in managing the government agricultural foundation projects in the Department of Agriculture and Husbandry of Ningxia Hui Autonomous Region. Her Ph.D. research work was mainly in the fields of fat metabolism, gene microarray chip data analysis. Part of her Ph.D. research work was completed in Sainte-Justine Hospital of Montreal University in 2007. Dr. Zhang then jointed Beijing CEVA HUADU biological Co.,Ltd, as a director leading the R&D team for animal vaccine development. Her work focused on Adenovirus based rabies vaccine pilot plant manufacturing and chlamydia vaccine development. She joined Beijing Zheife Lvzhu Biopharmaceutical Co.,Ltd in 2010 as a vice president. She is currently leading the effort of Rotavirus vaccine development and managing the company business development, international technology in-licensing, government funding application, product and clinical trial registration, product marketing promotion etc.
Founder & General Manager
Beijing Minhai Biotechnology Co.,Ltd
With 27 year experience in vaccine R&D, production and management, Dr.Zheng Haifa has led several vaccines development, including rabies vaccine, SARS vaccine and has been leader of several 863 national and Beijing science and technology projects. He is also the technology evaluation expert for national 863 projects.He is CPPCC standing committee of DaXing district, adjunct professor of Third Military Medical University of China PLA, Beijing Normal University and Changchun University of Science and Technology.
Executive Vice President
Shanghai Zerun Biotech Co., Ltd. , China
Dr. Zeng is currently Executive Vice President at Shanghai Zerun Biotechnology Co., Ltd., responsible for preclinical and clinical product development, and cGMP clinical manufacturing of novel vaccines and biologics (including HPV vaccine against cervical cancer). Prior to joining Zerun Biotechnology, Dr. Zeng was the Director of Process Development at Dendreon Corporation, leading cell culture, purification process development, and bioengineering service teams to develop novel antigens and also providing scientific and technological support to the antigen manufacturing for Provenge®, the first FDA-approved autologous cellular immunotherapy. Recently Dr. Zeng has been leading HPV Cervical Cancer Vaccine projects into Phase III clinical trial and commercialization in China. He brings in 20 years of process development, cGMP manufacturing, and managerial experience from Fuji Diosynth, GSK, Shire, Lonza and Dendreon. Dr. Zeng received a PhD. degree in Biochemical Engineering from the State University of New York at Buffalo, and a MBA from the University of Massachusetts at Amherst. Dr. Zeng is also an affiliated Associate Professor in Chemical Engineering Department of the University of Washington.